Use the links below to access our reports, or scroll down to use the search function to explore all of our publications including peer-reviewed papers and briefing papers.

Browse all publications


BibTex format

author = {Ward, H and Atchison, C and Whitaker, M and Ainslie, KEC and Elliott, J and Okell, L and Redd, R and Ashby, D and Donnelly, C and Barclay, W and Darzi, A and Cooke, G and Riley, S and Elliott, P},
doi = {10.1038/s41467-021-21237-w},
journal = {Nature Communications},
pages = {1--8},
title = {SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.},
url = {},
volume = {12},
year = {2021}

RIS format (EndNote, RefMan)

AB - England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here we report from the REal-time Assessment of Community Transmission-2 (REACT-2) national study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI: 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection rather than differential experience of disease or care.
AU - Ward,H
AU - Atchison,C
AU - Whitaker,M
AU - Ainslie,KEC
AU - Elliott,J
AU - Okell,L
AU - Redd,R
AU - Ashby,D
AU - Donnelly,C
AU - Barclay,W
AU - Darzi,A
AU - Cooke,G
AU - Riley,S
AU - Elliott,P
DO - 10.1038/s41467-021-21237-w
EP - 8
PY - 2021///
SN - 2041-1723
SP - 1
TI - SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.
T2 - Nature Communications
UR -
UR -
UR -
VL - 12
ER -